TY - JOUR
T1 - Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches
AU - Needham, M.
AU - Mastaglia, Francis
PY - 2007
Y1 - 2007
N2 - Inclusion body myositis is the most common acquired muscle disease in older individuals, and its prevalence varies among countries and ethnic groups. The aetiology and pathogenesis of sporadic inclusion body myositis are still poorly understood; however genetic factors, ageing, and environmental triggers might all have a role. Unlike other inflammatory myopathies, sporadic inclusion body myositis causes slowly progressing muscular weakness and atrophy, it has a distinctive pattern of muscle involvement, and is unresponsive to conventional forms of immunotherapy. This review covers the clinical presentation, diagnosis, treatment, and the latest information on genetic susceptibility and pathogenesis of sporadic inclusion body myositis.
AB - Inclusion body myositis is the most common acquired muscle disease in older individuals, and its prevalence varies among countries and ethnic groups. The aetiology and pathogenesis of sporadic inclusion body myositis are still poorly understood; however genetic factors, ageing, and environmental triggers might all have a role. Unlike other inflammatory myopathies, sporadic inclusion body myositis causes slowly progressing muscular weakness and atrophy, it has a distinctive pattern of muscle involvement, and is unresponsive to conventional forms of immunotherapy. This review covers the clinical presentation, diagnosis, treatment, and the latest information on genetic susceptibility and pathogenesis of sporadic inclusion body myositis.
U2 - 10.1016/S1474-4422(07)70171-0
DO - 10.1016/S1474-4422(07)70171-0
M3 - Article
SN - 1474-4422
VL - 6
SP - 620
EP - 631
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 7
ER -